Giulia Siravegna

发表

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

A. Bardelli, M. Buscarino, F. Di Nicolantonio, 2014, Science Translational Medicine.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Enzo Medico, Roberta Schiavo, F. Nicolantonio, 2012, Nature.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Gad Getz, Ignaty Leshchiner, Dejan Juric, 2017, Cancer discovery.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Beatriz Bellosillo, Enzo Medico, Giuseppe Rospo, 2015, Nature Medicine.

Integrating liquid biopsies into the management of cancer

A. Bardelli, S. Marsoni, G. Siravegna, 2017, Nature Reviews Clinical Oncology.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Andrea Bertotti, Simona Corso, Maria Apicella, 2013, Cancer discovery.

Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers

Tiziana Venesio, Anna Sapino, A. Bardelli, 2017, Pathobiology.

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.

Mari Mino-Kenudson, Giorgio Corti, Mauro Truini, 2016, Cancer discovery.

Blood circulating tumor DNA for non‐invasive genotyping of colon cancer patients

A. Bardelli, G. Siravegna, Alberto Bardelli, 2016, Molecular oncology.